These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15893927)

  • 1. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
    Honorio KM; Garratt RC; Andricopulo AD
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3119-25. PubMed ID: 15893927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
    Honório KM; Garratt RC; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Mar; 25(6):921-7. PubMed ID: 17055759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-activity relationships for a series of selective estrogen receptor-beta modulators.
    Salum LB; Polikarpov I; Andricopulo AD
    SAR QSAR Environ Res; 2007; 18(7-8):711-27. PubMed ID: 18038369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
    Salum Lde B; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
    Zhang T; Zhou JH; Shi LW; Zhu RX; Chen MB
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2156-60. PubMed ID: 17307356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
    Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
    Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists.
    Doddareddy MR; Lee YJ; Cho YS; Choi KI; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Jul; 12(14):3815-24. PubMed ID: 15210148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
    Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
    Kainuma M; Kasuga J; Hosoda S; Wakabayashi K; Tanatani A; Nagasawa K; Miyachi H; Makishima M; Hashimoto Y
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3213-8. PubMed ID: 16617018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
    Kaur K; Talele TT
    J Mol Graph Model; 2008 Nov; 27(4):409-20. PubMed ID: 18774323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the molecular requirements for the anti-obesity activity of a series of CB1 ligands.
    Weber KC; De Lima EF; De Mello PH; Da Silva AB; Honório KM
    Chem Biol Drug Des; 2010 Oct; 76(4):320-9. PubMed ID: 20887613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of cannabinoid-1 receptor antagonists for the treatment of obesity: hologram QSAR model for biarylpyrazolyl oxadiazole ligands.
    Ye M; Dawson MI
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3310-5. PubMed ID: 19427207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hologram QSAR model for the prediction of human oral bioavailability.
    Moda TL; Montanari CA; Andricopulo AD
    Bioorg Med Chem; 2007 Dec; 15(24):7738-45. PubMed ID: 17870541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
    J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
    Takahashi M; Kanayama T; Yashiro T; Kondo H; Murase T; Hase T; Tokimitsu I; Nishikawa J; Sato R
    Biochem Biophys Res Commun; 2008 Aug; 372(3):395-9. PubMed ID: 18457666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
    Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.